Circadian Thermal Sensing to Detect Breast Disease
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 1/5/2019 |
| Start Date: | June 2015 |
| End Date: | February 2020 |
| Contact: | Marie Norell, B.A., CCRA |
| Email: | manorell@cyrcadiahealth.com |
| Phone: | 775-233-1211 |
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
The purpose of this study is to determine if Cyrcadia's Circadian Biometric Recorder (CBR™),
which is attached to soft biometric patches worn on the body, can improve early breast cancer
detection along with mammography or as a stand alone device.
which is attached to soft biometric patches worn on the body, can improve early breast cancer
detection along with mammography or as a stand alone device.
The Cyrcadia CBR™ (Circadian Biometric Recorder) includes wearable biometric patches and a
detachable data recording device. The CBR™ records chronobiologic data while the patient is
totally ambulatory and going about her normal daily routine. Following removal of the
detachable data recording device from the wearable biometric patches, the data is transferred
to a computer for analysis. The Cyrcadia CBR™ will be placed on the patient for the duration
of 2 to 24 hours. There is no restriction of daily activity. The study subject is requested
to sponge bathe rather than shower while wearing the device, keeping the device dry during
the testing procedure. After this period, the CBR™ will be removed and the data will be
transferred to a computer for analysis.
The primary endpoint of this 173 patient study is to determine the accuracy of Cyrcadia CBR™
as a supplemental screening device to mammography and ultrasound in predicting a diagnosis of
breast cancer. Specific emphasis will be on the utilization of the CBR as a secondary
screening device to reduce the number of biopsies currently performed on non-cancerous
tissue. A secondary emphasis will be on the CBR to act as an improved screening solution over
mammography specifically in those patients with dense breast parenchymal tissue.
Other endpoints of the study are:
- to determine the accuracy of Cyrcadia CBR™, including the positive predictive value,
negative predictive value, false negative rate and false positive rate.
- to determine the optimal wear time for the Cyrcadia CBR™.
- to demonstrate substantial equivalent or improved results when applied to Cyrcadia
original patient case study with identical advanced neural network analysis
computational results.
Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status.
detachable data recording device. The CBR™ records chronobiologic data while the patient is
totally ambulatory and going about her normal daily routine. Following removal of the
detachable data recording device from the wearable biometric patches, the data is transferred
to a computer for analysis. The Cyrcadia CBR™ will be placed on the patient for the duration
of 2 to 24 hours. There is no restriction of daily activity. The study subject is requested
to sponge bathe rather than shower while wearing the device, keeping the device dry during
the testing procedure. After this period, the CBR™ will be removed and the data will be
transferred to a computer for analysis.
The primary endpoint of this 173 patient study is to determine the accuracy of Cyrcadia CBR™
as a supplemental screening device to mammography and ultrasound in predicting a diagnosis of
breast cancer. Specific emphasis will be on the utilization of the CBR as a secondary
screening device to reduce the number of biopsies currently performed on non-cancerous
tissue. A secondary emphasis will be on the CBR to act as an improved screening solution over
mammography specifically in those patients with dense breast parenchymal tissue.
Other endpoints of the study are:
- to determine the accuracy of Cyrcadia CBR™, including the positive predictive value,
negative predictive value, false negative rate and false positive rate.
- to determine the optimal wear time for the Cyrcadia CBR™.
- to demonstrate substantial equivalent or improved results when applied to Cyrcadia
original patient case study with identical advanced neural network analysis
computational results.
Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status.
Inclusion Criteria:
- Women with a BI-RADS category 4 or 5 designation on mammogram
- Women with a BI-RADS category 4 or 5 designation on breast ultrasound
- Women with a BI-RADS category 4 or 5 designation on breast MRI
- Women who are willing to undergo a complete evaluation and/or biopsy procedure if
recommended by the treating physician
Exclusion Criteria:
- Less than 21 years of age
- Unable to sign the consent form
- Pregnant or lactating
- Physically unable to wear the Cyrcadia CBR™ for 6 hours
- Previous mastectomy
- Any breast surgery or biopsy within the last 90 days
- Any trauma to the breast within the last 90 days
- Any biopsy or treatment for the BI-RADS category 4 or 5 abnormality
- Refusal to undergo recommended diagnostic evaluation of the BI-RADS category 4 or 5
abnormality
We found this trial at
2
sites
El Camino Hospital El Camino Hospital is a nonprofit organization with hospital campuses in Mountain...
Click here to add this to my saved trials
Click here to add this to my saved trials